MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ
1.530
+0.090
+6.25%
After Hours: 1.490 -0.04 -2.61% 18:49 05/09 EDT
OPEN
1.440
PREV CLOSE
1.440
HIGH
1.540
LOW
1.430
VOLUME
206.02K
TURNOVER
--
52 WEEK HIGH
9.25
52 WEEK LOW
0.8700
MARKET CAP
49.91M
P/E (TTM)
-0.2882
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OTLK last week (0428-0502)?
Weekly Report · 5d ago
Weekly Report: what happened at OTLK last week (0421-0425)?
Weekly Report · 04/28 12:24
Weekly Report: what happened at OTLK last week (0414-0418)?
Weekly Report · 04/21 12:23
Weekly Report: what happened at OTLK last week (0407-0411)?
Weekly Report · 04/14 12:08
Outlook Therapeutics Approves Retention Incentive for CFO
TipRanks · 04/11 22:22
OUTLOOK THERAPEUTICS - FDA DETERMINED CLASS 2 REVIEW FOR OUTLOOK THERAPEUTICS' BLA FOR ONS-5010- SEC FILING
Reuters · 04/08 21:01
Outlook Therapeutics gets FDA review acceptance for wet AMD treatment
Seeking Alpha · 04/08 14:42
Outlook Therapeutics Resubmits BLA For ONS-5010 In Wet AMD
NASDAQ · 04/08 13:10
More
About OTLK
More
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Recently
Symbol
Price
%Change

Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.